With over 20 years of experience in the biopharmaceutical industry, Joseph W. Siemiatkoski is a proven development scientist with extensive strategic and operational experience in biopharmaceutical product development and commercialization.
Before joining BPTC, Mr. Siemiatkoski was Sr. Director of Product Development at Epirus Biopharmaceuticals where he was responsible for process development and comparability/characterization activities for biosimilar antibodies; and Director, Analytical and Downstream Process Development at Percivia where he was responsible for analytical and downstream process development to support CRO/CMO activities for a variety of products (vaccines, antibodies, clotting factors) using the PER.C6 cell line. He has also held positions in process development at Biogen, Genetics Institute and Genzyme (Integrated Genetics).
Mr. Siemiatkoski is focused on transforming research into treatments, and has assisted in the development of a range of biological and biopharmaceutical products and the successful commercialization of several of these products. He is an associate director at CaSSS, and serves on the organizing committee for the WCBP where he frequently leads workshops and round table discussion on topics spanning the interface of analytics and regulatory affairs.
Mr. Siemiatkoski has also served as a USP/NF Scientific Advisory Panel member, and contributed to the chapters on electrophoresis and carbohydrate analysis. He has been a co-author on several peer-reviewed scientific articles ranging from separation science to carbohydrate chemistry, and has co-authored white papers on regulatory issues ranging from characterization of biopharmaceuticals to risk assessment with members of the FDA.
Mr. Siemiatkoski holds a B.S. in chemistry/biochemistry from Rensselaer Polytechnic Institute.